|
|
|
| home > white papers > R&D to Product: How to Reduce Costly Scale-Up Problems - Natoli Engineering Company, Inc. |
|
|
 WHITE PAPERS |
|
Natoli Engineering Company, Inc.
|
|
R&D to Product: How to Reduce Costly Scale-Up Problems
|
|
When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
CPhI MEA expert:growing domestic manufacturing is creating new opportunities for international Pharma in the Middle East
Abu Dhabi, 5th August 2019: CPhI Middle East expert Emad Shabbir, Director at EMAD Trade House, states favorable conditions and legislative regulations in Saudi Arabia are resulting in a boom of manufacturers and CMOs partnerships with international pharma companies. With the strategic cooperation between regional generic companies and multinational pharma companies, driving increased local production.
More info >> |
|
 |
White Papers |
 |
|
Translating Cancer Genomics Into A Personalised Approach For Cancer Patients
PRA Health Sciences (PRA)
Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >> |
|
 |
Industry Events |
 |
Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology
27 August - 21 November 2019, Barcelona, Spain
On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >> |
|
|
|
